Overview of Dr. Coyle
I am an expert in Multiple Sclerosis and Neurologic Lyme Disease. I've been named as one of Castle Connolly Top Doctors® since 1999, most recently being named Top Doctors on New York Magazines 2021 list. I've held multiple leadership positions at the American Board of Psychiatry and Neurology, the American Academy of Neurology, the American Neurological Association, and the National MS Society. I've also served as an adviser to the Food and Drug Administration and the Institute of Medicine. I have received research funding from the NIH and the National MS Society, and am actively engaged in studies to understand and treat these diseases.
Office
179 N Belle Mead Rd
East Setauket, NY 11733Fax+1 631-638-4374
Education & Training
- Johns Hopkins UniversityFellowship, Neuroimmunology & Multiple Sclerosis, 1978 - 1980
- Johns Hopkins UniversityResidency, Neurology, 1975 - 1978
- New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1974 - 1975
- Johns Hopkins University School of MedicineClass of 1974
Certifications & Licensure
- NY State Medical License 1975 - 2026
- MD State Medical License 1978 - 1980
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Invited Speaker Sanofi Genzyme, Real World Experience with Teriflunomide in Multiple Sclerosis Webinar, 2021
- Invited Speaker Novartis, Jordan SPMS Advisory Board, 2021
- Invited Speaker Sanofi Genzyme, KSA MS FORUM, 2021
- Join now to see all
Publications & Presentations
PubMed
- How Do I Approach the Evaluation and Treatment of Early Lyme Disease?Steven E Schutzer, Patricia K Coyle
NEJM Evidence. 2024-08-01 - 2 citationsSARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.Roham Hadidchi, Stephen H Wang, David Rezko, Sonya Henry, Patricia K Coyle
Multiple Sclerosis and Related Disorders. 2024-06-01 - 1 citationsTwenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn
Neurology and Therapy. 2024-04-01
Journal Articles
- Ofatumumab Versus Teriflunomide in Multiple SclerosisStephen L Hauser, Amit Bar-Or, Patricia K Coyle, Alexandra Goodyear, The New England Journal of Medicine
Authored Content
- Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020
- Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020
Press Mentions
- Multiple Sclerosis Has a Misdiagnosis ProblemJune 15th, 2023
- Prior Treatment Status: Impact on the Efficacy and Safety of Teriflunomide in Multiple SclerosisOctober 6th, 2020
- SPMS Triggers and Treatments Among Focus of Expert Panel in Video Series by AJMCSeptember 10th, 2019
- Join now to see all
Professional Memberships
- Member
- National Multiple Sclerosis SocietyMedical Board
- Scientific Advisory PanelMember
- Congressionally Directed Medical Research Programs (CDMRP)FDA CNS-PNS Advisory Panel
- American Neurological Association (ANA)Member
- NYSMSC Executive CommitteeMember
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHealthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: